Compare drug alternatives

Haegarda® Alternatives

Haegarda®(C1 esterase inhibitor)
Takhzyro®(lanadelumab)
Prescription Only
Haegarda is a synthetic version of a blood protein that regulates swelling in the body. Individuals with Hereditary Angioedema (HAE) lack sufficient levels of this protein,...
Prescription Only
Takhzyro is a monoclonal antibody that controls an overactive enzyme in individuals with hereditary angioedema, a rare genetic immune system disorder. It is prescribed to prevent...
Dosage & Administration
Administration
Subcutaneous . Learn more.
Subcutaneous. Learn more.
Dosing
Administer 60 International Units per kg body weight twice weekly (every 3 or 4 days).. Learn more.
Adult and pediatric patients 12 years of age and older: administer 300 mg every 2 weeks. 6 to less than 12 years of age: administer 150 mg every 2 weeks. Pediatric patients 2 to less than 6 years of age: administer 150 mg every 4 weeks.. Learn more.
Latin Shorthand
Administer 60 IU/kg BW BID (q3-4d).. Learn more.
Adult and pediatric patients (≥12 years): 300 mg every 2 weeks. Patients aged 6 to <12 years: 150 mg every 2 weeks. Patients aged 2 to <6 years: 150 mg every 4 weeks.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
Assistance Expiration
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
Adverse reactions occurring in more than 4% of subjects treated with HAEGARDA were injection site reactions, hypersensitivity, nasopharyngitis and dizziness.. Learn more.
The most common adverse reactions (≥10%) are injection site reactions, upper respiratory infections, headache, rash, dizziness, diarrhea, and myalgia.. Learn more.
Mechanism of Actions (MoA)
Drugs used in Hereditary Angioedema. Learn more.
Drugs used in Hereditary Angioedema. Learn more.
Special Populations
1. Is it safe to use HAEGARDA during pregnancy?

There are no prospective clinical data from HAEGARDA use in pregnant women. However, limited retrospective data suggest that C1-INH treatment during pregnancy did not lead to adverse events. The estimated background risk of birth defects and miscarriage in the general U.S. population is 2-4% and 15-20%, respectively.

2. What is known about HAEGARDA use during lactation?

There is no information available about the presence of HAEGARDA in human milk, its impact on breastfed infants, or its effects on milk production. The decision to breastfeed should consider the benefits of breastfeeding and the mother's clinical need for HAEGARDA, while also evaluating potential adverse effects on the breastfed infant.

3. Has HAEGARDA been tested in pediatric patients?

Yes, the safety and effectiveness of HAEGARDA were evaluated in a subgroup of patients aged 8 to <17 years in clinical trials, and the results were consistent with overall study results.

4. Is HAEGARDA suitable for use in geriatric patients?

Clinical studies of HAEGARDA did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects. However, reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for elderly patients should be cautious and typically start at the lower end of the dosing range, considering factors like decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.